I Hate Dialysis Message Board
Welcome, Guest. Please login or register.
March 28, 2024, 01:40:19 PM

Login with username, password and session length
Search:     Advanced search
532606 Posts in 33561 Topics by 12678 Members
Latest Member: astrobridge
* Home Help Search Login Register
+  I Hate Dialysis Message Board
|-+  Dialysis Discussion
| |-+  Dialysis: News Articles
| | |-+  Fresenius Collaborates in Regenerative Medicine
0 Members and 1 Guest are viewing this topic. « previous next »
Pages: [1] Go Down Print
Author Topic: Fresenius Collaborates in Regenerative Medicine  (Read 2500 times)
kickingandscreaming
Elite Member
*****
Offline Offline

Gender: Female
Posts: 2268


« on: June 02, 2016, 12:24:57 PM »

Fresenius Medical Care has established a subsidiary focusing on regenerative medicine. Unicyte AG will pursue research into kidney and liver diseases, diabetes and cancer, and will work with additional partners when needed to advance these projects, the company said in a release.

Fresenius Medical Care has collaborated with the University of Turin since 2003. The first result of their joint research under the direction of Prof. Giovanni Camussi, Scientific Director of the university’s Torino Stem Cell Project, was the isolation and characterization of a human stem cell population from an adult liver. These liver stem cells are easy to isolate, capable of being multiplied without limit and transferrable into various other cell types, making them a potential option for regenerative medicine.

Other discoveries were functional pancreatic islets (which mimic the function of pancreatic cells) for the treatment of diabetes, and stem cell-derived extracellular vesicles (particles that support communication between cells) for the treatment of kidney and liver diseases as well as cancer. The first research results were converted recently into preclinical development projects.
http://www.nephrologynews.com/fresenius-medical-care-creates-regenerative-medicine-subsidiary/?utm_source=newsletter_060216&utm_medium=email&utm_campaign=newsletter

The company said it will pursue the development projects up until the stage of clinical studies on humans. The long-term goal is to improve the lives of kidney and liver disease, diabetes and cancer patients.

“This is an outstanding example of collaboration between industry and science,” said Gianmaria Ajani, Rector of the University of Turin. “It is not only driving the development of new technologies, but is providing an educational opportunity for young people. Unicyte will attract more international sponsors and investors, and in this way secure, long-term jobs can be created.”
Logged

Diagnosed with Stage 2 ESRD 2009
Pneumonia 11/15
Began Hemo 11/15 @6%
Began PD 1/16 (manual)
Began PD (Cycler) 5/16
Pages: [1] Go Up Print 
« previous next »
 

Powered by MySQL Powered by PHP SMF 2.0.17 | SMF © 2019, Simple Machines | Terms and Policies Valid XHTML 1.0! Valid CSS!